Macrocycle Diary's New Entry: Ensemble Deal with Boehringer

By entering a potential $186 million research pact with Ensemble Therapeutics Inc. for synthetic macrocycles, Boehringer Ingelheim GmbH became the latest to place its bet on a newish, challenging approach that could combine the all-in-a-pill possibility of small molecules with the biological bull's-eye talent of large ones.